DOCSLIB.ORG

(12) Patent Application Publication (10) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub US 2005.0014697A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0014697 A1 Stamler et al. (43) Pub. Date: Jan. 20, 2005 (54) COMPOSITIONS AND METHODS FOR on Feb. 18, 2004. Provisional application No. 60/550, MODULATING S-NITROSOGLUTATHONE 833, filed on Mar. 4, 2004. REDUCTASE Publication Classification (76) Inventors: Jonathan S. Stamler, Chapel Hill, NC (US); Limin Liu, Durham, NC (US) (51) Int. Cl." ........................ A61K 38/18; A61K 31/198 (52) U.S. Cl. .............................................. 514/18: 514/565 Correspondence Address: MINTZ, LEVIN COHN FERRIS GLOWSKY & POPEO (57) ABSTRACT 666 THIRDAVENUE Disclosed herein are methods and compositions for modu NEW YORK, NY 10017 (US) lating the levels and/or activity of S-nitroSoglutathione (21) Appl. No.: 10/861,304 reductase (GSNOR) in vivo or in vitro. Specifically dis closed are GSNOR deletion constructs, host cells and non (22) Filed: Jun. 4, 2004 human mammals comprising GSNOR deletions, and meth ods of screening employing GSNOR deletion mutants. Also Related U.S. Application Data Specifically disclosed are reagents and procedures for mea Suring, monitoring, or altering GSNOR levels or activity (as (60) Provisional application No. 60/476,055, filed on Jun. well as nitric oxide and S-nitroSothiol levels) in connection 4, 2003. Provisional application No. 60/545,965, filed with various medical conditions. Patent Application Publication Jan. 20, 2005 Sheet 1 of 27 US 2005/0014697 A1 A Wild-ild-type allelee Ab-SS) s Targetingtly vector- PGKn xs / B / PGK h N 2. 4 is 9 2. so Fse %2 5 E.a so g 2 4. is S is 40an s. 2 2 35 r 2.% wer they Heart Lung Spleen Thymus y: atweaning F.G. 1 Patent Application Publication Jan. 20, 2005 Sheet 2 of 27 US 2005/0014697 A1 A B C 80 92 10 360 a Se 2. 2 6 X 4 E 40 3 S O 9 E 5 20 g 9 2. is t WT KO WT KO SNO FeNO D Redblood Cell Pierra GSeoGye-ND Remi-Abuadr-SNO Largsgata Wasecarterestigato Wasodilation during ypgdstagfig demand No deficiency FIG 2 Patent Application Publication Jan. 20, 2005 Sheet 3 of 27 US 2005/0014697 A1 A 1 B 10 9 or 7 7 w ad o 6 2 2 e C a O 1 2 3 4. 5 6 O 1. 2 3 4. 5 6 Days after LPS Days after LPS C 1 D 1 9 s 2 7 7 3 3 S. O 1 2 3 4. S 6 Days after LPS Days after LPS E 2 2 t O 2 3 4 5 & 7 Days after CLP FIG. 3 Patent Application Publication Jan. 20, 2005 Sheet 4 of 27 US 2005/0014697 A1 A 40 ++ total B 1200 -- total 000 30 S -- low-mass 'o 2 s 800 asE 2 retS. 600 sE s 400 2 200 O O PBS LPS24 LPS48 PBS LPS24h LPS48h C 8 D 6 E 4. s g3 A 5 E3 22 re. 2 9. O D PBS LPS24h LPS48h LPS 24h LPS48h 0 FIG. 4 Patent Application Publication Jan. 20, 2005 Sheet 5 of 27 US 2005/0014697 A1 - PBS LPS24h LPS48h PBS LPS24h LPS48h PES is lish PBS LPS24h LPS48h ps ships G 140 H2 2 s 100 S. O a tha O s - - 2. t 2 3 4 5) 8) to PBS PS24h LPS48h SNO (pmol mg) F.G. 5 Patent Application Publication Jan. 20, 2005 Sheet 6 of 27 US 2005/0014697 A1 FIG 6 Patent Application Publication Jan. 20, 2005 Sheet 7 of 27 US 2005/0014697 A1 A 1200 B 40 C D 100 OO) 35 90 30 8 as 800 'o pa s E 25 s to 600 as 20 S. wn E 5 so O 3, 15 8 2. O 10 50 20 e 5 4. O 1 2 3 4 S 6 LPS 24h LPS 48h LPS48h Days after LPS FIG. 7 Patent Application Publication Jan. 20, 2005 Sheet 8 of 27 US 2005/0014697 A1 5 to H H at at & 3s s ck O C 3. S bf) b) w b e b vu h O (oosiu? Huo) dugoseqiad) in O Patent Application Publication Jan. 20, 2005 Sheet 9 of 27 US 2005/0014697 A1 a S5 S 33> 2. a 3O s- O2 : : < > O O N4 t > O Od s CD L M A A. O NZ V A A. C O C O O C O C C O lf C b) O lf) N N y yu Patent Application Publication Jan. 20, 2005 Sheet 10 of 27 US 2005/0014697 A1 9. Ek s Sa 9 O O CD I O O N4 O S. S. 92 S C2 e e g e. Oe Ce Oi sCo seO OOO Oe Cot Oe O (I u?irl) el-TI ITV Patent Application Publication Jan. 20, 2005 Sheet 11 of 27 US 2005/0014697 A1 cysNO (M) O 500 50 5 a GRK2 - - - - - - - - - - - - - ISO - - - - - - - - - - - - B-AR cysNO (uM) GRK2 32P-rhodopsin FIG. 11B 5000 s 20000 L CPM 9.4000 a. 3000 s 10000 2000 3.t 5 1000 8 E O saxx, s O S s s . c) s e a ge Yala o 2-- o 39 FIG. 12A FIG. 12B 7 as s S s 80 92 x s 2 - SO s 34 g 40 33s a g 2 X cap g 20 2 1 s O : O PBS ISO GSNO ISO+GSNO PBS ISO GSNO SO-GSNO PBS ISO GSNO GSNO+SO F.G. 13A F.G. 13B FIG. 13C Patent Application Publication Jan. 20, 2005 Sheet 13 of 27 US 2005/0014697 A1 LOCUS NM 000671 2496 bp mRNA linear DEFINITION Homo sapi ens alcohol dehydrogenase 5 (class III), chi polypeptide (ADH5), mRNA. ACCESSION NM 000671 COMPLETENESS: full length. FEATURES Location/Qualifiers Solice . 2496 A chromosome="4" 1. 2496 /gene="ADH5" Anote= "synonyms: FDH, ADHX, ADH-3" misc feature 1. /gene="ADH5" Wnote= "alternative start site; active site" variation complement (4) /replace="T" /replace="C" /db Xref="dbSNP : 1154400" misc feature 83 /gene="ADH5" /note= "alternative start site; active site" Inisc feature 85 /gene="ADH5" /note= "alternative start site; active site" CDS 63 . .287 /gene="ADH5" /EC number="l. 1. l. 1" /EC number="1.2.1.1" /note= "Alcohol dehydrogenase (class III), chi polypeptide; glutathione-dependent formaldehyde dehydrogenase; go function : formaldehyde dehydrogenase (glutathione) activity (goid 0.004327) evidence TAS) (pinid 84.60164); go function: fatty acid binding Igoid OOO5504) (evidence TAS) pmid 84.60164); go function: electron transporter activity (goid 0005489) evidence TAS) pmid 846O164); go function: alcohol dehydrogenase activity, zinc-dependent (goid OOO4024) evidence IEA) ; go function : zinc ion binding (goid OOO827O) evidence IEA) ; go function: oxidoreductase activity goid OO16491) evidence IEA); go function: alcohol dehydrogenase activity, metal ion-independent goid 0004023) evidence IEA) ; go function: alcohol dehydrogenase activity, iron-dependent goid 0004 025) evidence IEA) ; go process: ethanol oxidation (goid 0006069) (evidence TAS) (pmid 84.60164); go process: alcohol metabolism (goid 0006066 (evidence NR) FIG. 15A Patent Application Publication Jan. 20, 2005 Sheet 14 of 27 US 2005/0014697 A1 /codon start=1 /product = "class III alcohol dehydrogenase 5 chi subunit" /protein id="NP OOO662. 2" /db xref="GI: 11496891" /db xref="GenerD: 128." /db Xref="Locus ID: 128." /db xref="MIM:103710" /translation= "MANEVIKCKAAVAWEAGKPLSIEEIEVAPPKAHEVRIKIIATAV CHTDAYTLSGADPEGCFPVILGHEGAGIVESVGEGVTKLKAGDTVIPLYIPOCGECKF CLNPKTNLCOKIRVTOGKGLMPDGTSRFTCKGKTILHYMGTSTFSEYTVVADISVAKI DPLAPLYKVCILGCGSTGYGAAVNTAKLEPGSWCAVFGLGGWGLAVIMGCKVAGASR IIGVDINKDKFARAKEFGATECINPQDSKPIOEVLIEMTDGGVDYSFECIGNVKVMR AALEACHKGWGVSVVVGVAASGEEIATRPFQLVTGRTWKGTAFGGWKSVESVPKLVSE YMSKKIKVDEFWTHNLSFDEINKAFELMHSGKSIRTVVK I misc feature 63. 1284 /gene="ADH5" /note="KOG0022; Region: Alcohol dehydrogenase, class III Secondary metabolites biosynthesis, transport and catabolism.)" /db xref="CDD: 1782.0" misc feature 559 .56 /gene="ADH5" /note= "important for formaldehyde dehydrogenase activity and activation by fatty acids; binding site" variation complement (359) /replace="T" /replace="C" /db xref="dbSNP: 94.45600." variation complement (475) /replace="T" /replace= "A" /db xref="dbSNP: 94.45599." variation 66. /gene="ADH5" /note= "WARNING: map location ambiguous" /replace="T" /replace="G" /db xref="dbSNP:1050636." variation 900 /gene="ADH5" /replace="T" /replace= "A" /db xref="dbSNP:1050637" variation complement (932) /replace="G" /replace= "A" /db xref="dbSNP:43927 09" variation 153 /gene="ADH5" /replace="T" /replace="C" /db Xref="dbSNP:2229168" FIG. 15B Patent Application Publication Jan. 20, 2005 Sheet 15 of 27 US 2005/0014697 A1 variation 158 /gene="ADH5" /note="WARNING: map location ambiguous" /replace="G" /replace="C" /db xref="dbSNP: 1803039." variation complement (1400) /note= "WARNING: map location ambiguous" /replace="T" /replace="C" /db xref="dbSNP:30883 06" variation 1478 /gene="ADH5" /replace="T" /replace="C" /db xref="dbSNP:12697" variation 504 /gene="ADH5" /replace="T" /replace="C" /db xref="dbSNP: 12106" polyA signal 527 . 1532 /gene="ADH5" /note= "alternative polyA signal." /evidence=experimental variation 1703 /gene="ADH5" /replace="G" /replace="A" /db xref="dbSNP:1803037" variation 779 /gene="ADH5" /replace="T" /replace="G" /db xref="dbSNP:13832" variation complement (1859) /replace="T" /replace="C" /db xref="dbSNP: 682 7292." variation 2OOO /gene="ADH5" /note="WARNING: map location ambiguous" /replace="T" /replace="C" /db xref="dbSNP:1061187." variation 217. /gene="ADH5" /replace="T" /replace="C" /db xref="dbSNP:1803.038" polyA signal 2376. .238 /gene="ADH5" /note= "alternative polyA signal" /evidence=experimental polyA site 2443 /gene="ADH5" /note= "alternative polyA site" /evidence=experimental FIG. 15C Patent Application Publication Jan. 20, 2005 Sheet 16 of 27 US 2005/0014697 A1 ORIGIN agC9gCaC9C accacagctic gag caccgCC Cttccggttg gagcCattgc aag.ccc.cccc 6. CacgCCCC gC ccccct cqct aggcgct.cgc cacgc.cCatg cctc.cgtogc tgcgc.ggCCC 121 accCCggatg totagoccCCC gCGCCdacca gaatc.cgtga acatggcgaa cgaggittatc 181 aagttgcaagg CtgcagttgC ttgggaggCt ggaaag.cctic totccataga ggagatagag 241 gtggcacccc caaaggct Ca tgaagttcga atcaagatca ttgccactgc ggtttgccac 301 accgatgcct at accCtgag tggagctgat Cctgagggitt gtttitccagt gatcttggga 361 Catgaaggtg Ctggaattgt ggaaagttgtt g9tgagggag ttactaagct galagg.cgggt 42 gacactgtca tCccact teta catcccacag tgttggaga at gcaaattittg totaaat CCt 48 aaala Ctala CC tttgccagaa gatalaga.gtc act Calaggga aaggattaat gccagatggit 54.
Load more

Recommended publications
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • NON-HAZARDOUS CHEMICALS May Be Disposed of Via Sanitary Sewer Or Solid Waste
    NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste (+)-A-TOCOPHEROL ACID SUCCINATE (+,-)-VERAPAMIL, HYDROCHLORIDE 1-AMINOANTHRAQUINONE 1-AMINO-1-CYCLOHEXANECARBOXYLIC ACID 1-BROMOOCTADECANE 1-CARBOXYNAPHTHALENE 1-DECENE 1-HYDROXYANTHRAQUINONE 1-METHYL-4-PHENYL-1,2,5,6-TETRAHYDROPYRIDINE HYDROCHLORIDE 1-NONENE 1-TETRADECENE 1-THIO-B-D-GLUCOSE 1-TRIDECENE 1-UNDECENE 2-ACETAMIDO-1-AZIDO-1,2-DIDEOXY-B-D-GLYCOPYRANOSE 2-ACETAMIDOACRYLIC ACID 2-AMINO-4-CHLOROBENZOTHIAZOLE 2-AMINO-2-(HYDROXY METHYL)-1,3-PROPONEDIOL 2-AMINOBENZOTHIAZOLE 2-AMINOIMIDAZOLE 2-AMINO-5-METHYLBENZENESULFONIC ACID 2-AMINOPURINE 2-ANILINOETHANOL 2-BUTENE-1,4-DIOL 2-CHLOROBENZYLALCOHOL 2-DEOXYCYTIDINE 5-MONOPHOSPHATE 2-DEOXY-D-GLUCOSE 2-DEOXY-D-RIBOSE 2'-DEOXYURIDINE 2'-DEOXYURIDINE 5'-MONOPHOSPHATE 2-HYDROETHYL ACETATE 2-HYDROXY-4-(METHYLTHIO)BUTYRIC ACID 2-METHYLFLUORENE 2-METHYL-2-THIOPSEUDOUREA SULFATE 2-MORPHOLINOETHANESULFONIC ACID 2-NAPHTHOIC ACID 2-OXYGLUTARIC ACID 2-PHENYLPROPIONIC ACID 2-PYRIDINEALDOXIME METHIODIDE 2-STEP CHEMISTRY STEP 1 PART D 2-STEP CHEMISTRY STEP 2 PART A 2-THIOLHISTIDINE 2-THIOPHENECARBOXYLIC ACID 2-THIOPHENECARBOXYLIC HYDRAZIDE 3-ACETYLINDOLE 3-AMINO-1,2,4-TRIAZINE 3-AMINO-L-TYROSINE DIHYDROCHLORIDE MONOHYDRATE 3-CARBETHOXY-2-PIPERIDONE 3-CHLOROCYCLOBUTANONE SOLUTION 3-CHLORO-2-NITROBENZOIC ACID 3-(DIETHYLAMINO)-7-[[P-(DIMETHYLAMINO)PHENYL]AZO]-5-PHENAZINIUM CHLORIDE 3-HYDROXYTROSINE 1 9/26/2005 NON-HAZARDOUS CHEMICALS May Be Disposed Of Via Sanitary Sewer or Solid Waste 3-HYDROXYTYRAMINE HYDROCHLORIDE 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE
    [Show full text]
  • Effect of L-Canavanine, an Inhibitor of Inducible Nitric Oxide Synthase, on Myocardial Dysfunction During Septic Shock
    J Nippon Med Sch 2002; 69（1） 13 ―Original― Effect of L-canavanine, an Inhibitor of Inducible Nitric Oxide Synthase, on Myocardial Dysfunction During Septic Shock Norihito Suzuki, Atsuhiro Sakamoto and Ryo Ogawa Department of Anesthesiology, Nippon Medical School Abstract Overproduction of nitric oxide（NO）by inducible NO synthase（iNOS）plays aroleinthe pathophysiology of septic shock. The depression of cardiac contractilityinsuchsituationsis mediated by proinflammatory cytokines, including interleukin-1β（IL-1β）, and tumor necrosis factor-α（TNF-α）. The effects of two NOS inhibitors with different isoform selectivity were compared in isolated working rat hearts. The depression of contractility by IL-1β and TNF-α was prevented by administration of a nonselective nitric oxide synthase inhibitor, NG-nitro-L- arginine methyl ester（L-NAME）or an inhibitor of inducible nitric oxide synthase, L-canavanine. In contrast, when L-NAME was administered in the absence of IL-1β and TNF-α, it depressed contractility over the 2h perfusion period by significantly reducing coronary flow. These results support current thinking that the depression of myocardial functionbyIL-1β and TNF-α is mediated, at least in part, by an intracardiac increase in inducible nitric oxide synthase, and that in contrast to L-NAME, the decline in coronary conductance seen in cytokine-treated is not prevented by L-canavanine hearts. L-canavanine shows selective inhibition of inducible nitric oxide synthase unlike the vasopressor action of L-NAME in cytokine-treated hearts. （J Nippon Med Sch 2002; 69: 13―18） Key words: nitric oxide（NO）, nitric oxide（NO）synthase, working heart, L-canavanine, NG-nitro-L-arginine methyl ester（L-NAME） We have previously demonstrated that admini- Introduction stration of L-canavanine or L-NAME attenuated the endotoxin-induced hypotension and vascular hypore- Nitric oxide（NO）may be produced within the activity to adrenaline, and the beneficial hemody- heart by either constitutive or inducible NO1,2.
    [Show full text]
  • Nitric Oxide Synthase Inhibitors As Antidepressants
    Pharmaceuticals 2010, 3, 273-299; doi:10.3390/ph3010273 OPEN ACCESS pharmaceuticals ISSN 1424-8247 www.mdpi.com/journal/pharmaceuticals Review Nitric Oxide Synthase Inhibitors as Antidepressants Gregers Wegener 1,* and Vallo Volke 2 1 Centre for Psychiatric Research, University of Aarhus, Skovagervej 2, DK-8240 Risskov, Denmark 2 Department of Physiology, University of Tartu, Ravila 19, EE-70111 Tartu, Estonia; E-Mail: [email protected] (V.V.) * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +4577893524; Fax: +4577893549. Received: 10 November 2009; in revised form: 7 January 2010 / Accepted: 19 January 2010 / Published: 20 January 2010 Abstract: Affective and anxiety disorders are widely distributed disorders with severe social and economic effects. Evidence is emphatic that effective treatment helps to restore function and quality of life. Due to the action of most modern antidepressant drugs, serotonergic mechanisms have traditionally been suggested to play major roles in the pathophysiology of mood and stress-related disorders. However, a few clinical and several pre-clinical studies, strongly suggest involvement of the nitric oxide (NO) signaling pathway in these disorders. Moreover, several of the conventional neurotransmitters, including serotonin, glutamate and GABA, are intimately regulated by NO, and distinct classes of antidepressants have been found to modulate the hippocampal NO level in vivo. The NO system is therefore a potential target for antidepressant and anxiolytic drug action in acute therapy as well as in prophylaxis. This paper reviews the effect of drugs modulating NO synthesis in anxiety and depression. Keywords: nitric oxide; antidepressants; psychiatry; depression; anxiety 1. Introduction Recent data from Denmark and Europe [1,2], indicate that brain disorders account for 12% of all direct costs in the Danish health system and 9% of the total drug consumption was used for treatment of brain diseases.
    [Show full text]
  • Maintenance of Renal Vascular Reactivity Contributes to Acute Renal Failure During Endotoxemic Shock
    Maintenance of Renal Vascular Reactivity Contributes to Acute Renal Failure during Endotoxemic Shock Jean-Jacques Boffa and William J. Arendshorst Department of Cell and Molecular Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Septic shock is characterized by hypotension and decreased systemic vascular resistance and impaired vascular reactivity. Renal vasoconstriction markedly contrasts with sepsis-induced generalized systemic vasodilation, which is strongly depen- dent on nitric oxide. Whether maintained renal vascular reactivity to vasoconstrictors contributes to the decrease in renal blood flow (RBF) and GFR observed during LPS-induced sepsis was tested by assessment of the acute effects of pressor agents on mean arterial pressure (MAP) and renal hemodynamics in endotoxemic and control mice. LPS-injected mice displayed lower MAP, RBF, and GFR than controls (P < 0.001). Despite a lower MAP, basal renal vascular resistance (RVR) was higher during endotoxemia (P < 0.02). Angiotensin II infusion produced a weaker MAP response in septic mice (24 versus 37%; P < 0.005), suggesting impaired vasoconstriction and hyporeactivity. A similar MAP increase was observed between groups during G norepinephrine (NE) infusion. The MAP increase to nitric oxide synthase inhibition by N -nitro-L-arginine methyl ester indicating a strong influence of nitric oxide in ,(0.01 ؍ L-NAME) was much greater in LPS-treated mice (41 versus 15%, P) sepsis. In contrast, the RBF and RVR responses to angiotensin II, NE, or L-NAME were similar in both groups. Moreover, vasopressin produced greater changes in MAP, RBF, and RVR in septic mice than in controls. Among the vasoconstrictor challenges, only NE ameliorated the decrease in GFR 14 h after LPS injection.
    [Show full text]
  • Downloaded 1018 Mrna Sequencing an Increasing Trend in Isocitrate Dehydrogenase 1(IDH1) and 301 Mrna Microarray Data from the CGGA Data- -Mutant Gliomas (Ohba Et Al
    Liu et al. Mol Med (2021) 27:52 https://doi.org/10.1186/s10020-021-00316-0 Molecular Medicine RESEARCH ARTICLE Open Access Overexpressed XRCC2 as an independent risk factor for poor prognosis in glioma patients Zhendong Liu1,3†, Wang Zhang2†, Xingbo Cheng2†, Hongbo Wang1, Lu Bian1, Jialin Wang1, Zhibin Han2, Yanbiao Wang1, Xiaoyu Lian1, Binfeng Liu1, Zhishuai Ren1, Bo Zhang1, Zhenfeng Jiang2, Zhiguo Lin2* and Yanzheng Gao1,3* Abstract Background: XRCC2, a homologous recombination-related gene, has been reported to be associated with a variety of cancers. However, its role in glioma has not been reported. This study aimed to fnd out the role of XRCC2 in glioma and reveal in which glioma-specifc biological processes is XRCC2 involved based on thousands of glioma samples, thereby, providing a new perspective in the treatment and prognostic evaluation of glioma. Methods: The expression characteristics of XRCC2 in thousands of glioma samples from CGGA and TCGA data- bases were comprehensively analyzed. Wilcox or Kruskal test was used to analyze the expression pattern of XRCC2 in gliomas with diferent clinical and molecular features. The efect of XRCC2 on the prognosis of glioma patients was explored by Kaplan–Meier and Cox regression. Gene set enrichment analysis (GSEA) revealed the possible cellular mechanisms involved in XRCC2 in glioma. Connectivity map (CMap) was used to screen small molecule drugs target- ing XRCC2 and the expression levels of XRCC2 were verifed in glioma cells and tissues by RT-qPCR and immunohisto- chemical staining. Results: We found the overexpression of XRCC2 in glioma. Moreover, the overexpressed XRCC2 was associated with a variety of clinical features related to prognosis.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2007/0161543 A1 Yu Et Al
    US 2007 O161543A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0161543 A1 Yu et al. (43) Pub. Date: Jul. 12, 2007 (54) N-(PHOSPHONOALKYL)-AMINO ACIDS, (52) U.S. Cl. .............................. 514/7: 514/114: 530/331; DERVATIVES THEREOF AND 558/170 COMPOSITIONS AND METHODS OF USE (76) Inventors: Ruey J. Yu, Chalfont, PA (US); Eugene J. Van Scott, Abington, PA (US) (57) ABSTRACT Correspondence Address: AKN GUMPSTRAUSS HAUER & FELD The present invention relates to an N-(phosphonoalkyl)- 6. COMMERCE SQUARE amino acid, a related compound or a derivative thereof, the 2005 MARKET STREET, SUITE 2200 N-(phosphonoalkyl)-amino acid, related compound or PHILADELPHIA, PA 19103 (US) derivative thereof being in a form as a free acid, salt, partial salt, lactone, amide or ester, or in Stereoisomeric or non (21) Appl. No.: 11/621,287 Stereoisomeric form, other than N-(phosphonomethyl)-gly (22) Filed: Jan. 9, 2007 cine or N.N-bis(phosphonomethyl)-glycine. Also included is a composition including an N-(phosphonoalkyl)-amino acid, Related U.S. Application Data a related compound or a derivative thereof in a form as a free (60) Provisional application No. 60/757,614, filed on Jan. acid, salt, partial salt, lactone, amide or ester, or in Stereoi 10, 2006. sy u. Is Someric or non-stereoisomeric form, and a cosmetically or pharmaceutically acceptable vehicle for topical or systemic Publication Classification administration to a mammalian Subject, as well as a method of administering an effective amount of Such a composition (51) Int. Cl. A6 IK 38/05 (2006.01) for alleviating or improving a condition, disorder, symptom A6 IK 3/66 (2006.01) or syndrome associated with at least one of a nervous, C07K 5/10 (2006.01) vascular, musculoskeletal or cutaneous system.
    [Show full text]
  • Canavanine Increases the Content of Phenolic Compounds in Tomato (Solanum Lycopersicum L.) Roots
    plants Article Canavanine Increases the Content of Phenolic Compounds in Tomato (Solanum lycopersicum L.) Roots Pawel Staszek 1,* , Urszula Krasuska 1, Magdalena Bederska-Błaszczyk 2 and Agnieszka Gniazdowska 1,* 1 Department of Plant Physiology, Institute of Biology, Warsaw University of Life Sciences-SGGW, Nowoursynowska 159, 02-776 Warsaw, Poland; [email protected] 2 Department of Botany, Institute of Biology, Warsaw University of Life Sciences-SGGW, Nowoursynowska 159, 02-776 Warsaw, Poland; magdalena_bederska_bł[email protected] * Correspondence: [email protected] (P.S.); [email protected] (A.G.) Received: 2 November 2020; Accepted: 14 November 2020; Published: 17 November 2020 Abstract: Canavanine (CAN) is a nonproteinogenic amino acid, and its toxicity comes from its utilization instead of arginine in many cellular processes. As presented in previous experiments, supplementation of tomato (Solanum lycopersicum L.) with CAN led to decreased nitric oxide (NO) level and induced secondary oxidative stress. CAN improved total antioxidant capacity in roots, with parallel inhibition of enzymatic antioxidants. The aim of this work was to determine how CAN-dependent limitation of NO emission and reactive oxygen species overproduction impact content, localization, and metabolism of phenolic compounds (PCs) in tomato roots. Tomato seedlings were fed with CAN (10 and 50 µM) for 24 or 72 h. Inhibition of root growth due to CAN supplementation correlated with increased concentration of total PCs; CAN (50 µM) led to the homogeneous accumulation of PCs all over the roots. CAN increased also flavonoids content in root tips. The activity of polyphenol oxidases and phenylalanine ammonia-lyase increased only after prolonged treatment with 50 µM CAN, while expressions of genes encoding these enzymes were modified variously, irrespectively of CAN dosage and duration of the culture.
    [Show full text]
  • Incorporation of Canavanine Into Protein of Vvalker Carcinosarcoma 256 Cells Cultured in Vitro
    Incorporation of Canavanine into Protein of VValker Carcinosarcoma 256 Cells Cultured in Vitro PAUL F. KRUSE, JR., PAT B. WHITE, HENRY A. CARTER, AND THOMAS A. McCoY (Biomedical Ds~ision, The Samuel Roberts Noble Foundation, Inc., Ardraore, Okla.) The inhibitory effect of canavanine on the exposure to the arginine-deficient medium for 4~) growth of Walker carcinosarcoma ~56 cells in minutes, sufficient L-canavanine .H2SO41 (~0.9 vitro was described in a previous report (9). Ap- mg. dissolved in Earle's balanced salt solution) parently, the inhibition rested in a competitive was added to produce a final concentration of 0.~0 interference of canavanine with the utilization of mM (10:1 ratio of canavanine to arginine). The arginine. inhibited cultures were incubated for ~4 hours and A number of recent reports have demonstrated allowed to stand at 4 ~ C. for ~ hours to free the that certain amino acid analogs--e.g., ethionine cells from the glass (1~); cell counts indicated a (6, 10, ~, ~6), p-fluorophenylalanine (2, 17, 9.~5), total of 104 X 106 cells. The contents of the flasks fl-~-thienylalanine (17), selenomethionine (4), 7- were combined and centrifuged in ~50-ml. bottles azatryptophan (18, 19), and tryptazan (3)--can for 6 minutes at 2750Xg. The cell buttons were be utilized in place of their respective metabolic transferred ~u a 15-ml. centrifuge tube and counterparts for protein synthesis. Accordingly, washed 3 times with 5-10-ml. portions of Earle's it was of interest to determine whether the tumor solution minus CaCl~. The cells were then ex- cells could utilize canavanine in this manner as a tracted successively with 80 per cent ethanol, substitute for arginine.
    [Show full text]
  • US5545625.Pdf
    ||||||||| US005545625A United States Patent 19 11 Patent Number: 5,545,625 Gross et al. (45. Date of Patent: Aug. 13, 1996 54). PREVENTING CONVERSION OF Schmidt, H. H. H. W., et al, Eur. J. Pharmacol. 154, CITRULLINE TO ARGINNOSUCCNATE TO 213–216 (1988). LIMIT PATHOLOGICAL NITRIC OXDE Sessa, W. C., et al. Proc. Natl. Acad. Sci. USA, OVERPRODUCTION 87.8607-8611 (Nov. 1990). Corbett, J. A., et al, Biochemistry 32, 13767-13770 (1993). 75 Inventors: Steven S. Gross, New York, N.Y.: Cross, A. H., et al., J. Clin. Invest. 93, 2684-2690 (1994). Owen W. Griffith, Milwaukee, Wis. McCartney-Francis, N., et al, J. Exp. Med. 178, 749–754 (1993). (73) Assignee: The Medical College of Wisconsin Misko, T. P., et al, Eur. J. Pharmacol. 233, 119-125 (1993). Research Foundation, Inc., Suarez-Pinzon, W. L., et al, Endocrinology, 134, 1006-1010 Milwaukee, Wis. (1994). Takada, S., et al., J. Biochem. 85, 1309-1314 (1979). 21 Appl. No.: 354,585 Freytag, S. O., Medline Abstract of J. Biol. Chem..., 259, 22 Filed: Dec. 12, 1994 3160-6 (1984). Grisolia, S., et al, The Urea Cycle, John Wiley & Sons, p. (51 Int. Cl." ......................... A61K 31/70; A61 K 31/195 191 (1976). 52 U.S. Cl. ............................ 514/33; 514/561; 514/564; Mitchell, J. A., et al, Eur, J. Pharmacol., 182, 573-576 514/930 (1990). 58 Field of Search .............................. 514/33, 561,564, Mulligan, M. S., et al. Proc. Natl. Acad. Sci. USA, 88, 514/930 6338-6342 (Jul 1991). Weinberg, J. B., et al., J. Exp. Med. 148, 651–660 (Feb.
    [Show full text]
  • Hazardous Waste Management Guide
    Hazardous Waste Management Guide Touro University California The university community plays a vital role in the management of hazardous wastes on our campus. Proper waste management is dependent upon your day-to-day handling of these wastes in your lab or worksite. Please read the Guide carefully. Last Updated: May 11, 2010 1 CONTACT INFORMATION Campus Emergency/Fire/Police (from a campus phone) 9-911 Vallejo Fire Department (non-emergency) 707-638-4526 Vallejo Police Department (non-emergency) 707-638-4321 Ambulance 707-552-1193 Campus Security (from a campus phone) 8-5804 Campus Facilities (from a campus phone) 8-5800 Campus Facilities (pager- after business hour) 707-551-6034 Biosafety Officer (from a campus phone) 8-5239 2 TABLE OF CONTENT SECTIONS INTRODUCTION.................................................................................................... 4 HAZARDOUS WASTE........................................................................................... 5 REQUIREMENTS FOR CHEMICAL WASTE...................................................... 5 CLASSIFICATION OF CHEMICAL WASTE....................................................... 7 GENERAL LABELING & PACKAGING …………………................................. 8 SPECIFIC LABELING & PACKAGING…………………................................... 9 DISPOSAL OF UNKNOWNS................................................................................. 15 BIOHAZARDOUS WASTE.................................................................................... 15 General Labeling, Packaging & Disposal
    [Show full text]
  • Thermochemistry of Amino Acids and Constrained Diamines
    W&M ScholarWorks Dissertations, Theses, and Masters Projects Theses, Dissertations, & Master Projects 2012 Thermochemistry of Amino Acids and Constrained Diamines Erica Jane Tullo College of William & Mary - Arts & Sciences Follow this and additional works at: https://scholarworks.wm.edu/etd Part of the Analytical Chemistry Commons, Biochemistry Commons, and the Physical Chemistry Commons Recommended Citation Tullo, Erica Jane, "Thermochemistry of Amino Acids and Constrained Diamines" (2012). Dissertations, Theses, and Masters Projects. Paper 1539623596. https://dx.doi.org/doi:10.21220/s2-vp4j-1g27 This Dissertation is brought to you for free and open access by the Theses, Dissertations, & Master Projects at W&M ScholarWorks. It has been accepted for inclusion in Dissertations, Theses, and Masters Projects by an authorized administrator of W&M ScholarWorks. For more information, please contact [email protected]. Thermochemistry of Amino Acids and Constrained Diamines Erica Jane Tullo Oxford, Pennsylvania Master of Science, The College of William and Mary, 2006 Bachelor of Science, Washington College, 2000 A Dissertation presented to the Graduate Faculty of the College of William and Mary in Candidacy for the Degree of Doctor of Philosophy Department of Applied Science The College of William and Mary January, 2012 APPROVAL PAGE This Dissertation is submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Committee Chair Marga t Hamilton Professor John C. Poutsma, Chemistry The College of William and Mary Professor Mark K. Hinders, C~r. Applied Science The College of William and Mary 2JtlUJJ Z1C- Assistant Professor Hannes C. Schniepp, Applied Science The College of William and Mary a~ ~L/b/ Professor David E."k:ranbuehl, cfiemistry The College of William and Mary ABSTRACT PAGE The gas-phase proton affinities of several highly basic amino acids and diamines were determined using the extended kinetic method in an ESI-quadrupole ion trap instrument.
    [Show full text]